JOURNAL OF INVESTIGATIVE MEDICINE, cilt.60, sa.1, ss.62-65, 2012 (SCI İndekslerine Giren Dergi)
Objectives: Patients with rheumatoid arthritis (RA) are known to be at increased cardiovascular risk. Etanercept is a tumor necrosis factor alpha (TNF-alpha) blocking agent that has been successfully used in the treatment of RA. We sought to assess the effects of etanercept on cardiac functions and lipid profile in RA patients without overt cardiac disease.